STOCK TITAN
  1. Home
  2. Sec-filings
  3. FBLG
  4. [8-K/A] FibroBiologics, Inc. Amends Material Event Report

[8-K/A] FibroBiologics, Inc. Amends Material Event Report

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
8-K/A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock FBLG logo
Fibrobiologics

NASDAQ:FBLG

FBLG Rankings

#5678 Ranked by Market Cap
N/A Ranked by Dividends

FBLG Latest News

Sep 11, 2025
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
Sep 10, 2025
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
Aug 27, 2025
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Jul 31, 2025
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jul 28, 2025
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

FBLG Latest SEC Filings

Aug 8, 2025
[8-K] FibroBiologics, Inc. Reports Material Event
Jul 31, 2025
[10-Q] FibroBiologics, Inc. Quarterly Earnings Report
Jul 18, 2025
[8-K] FibroBiologics, Inc. Reports Material Event
Jul 17, 2025
[SCHEDULE 13G/A] FibroBiologics, Inc. SEC Filing
Jul 3, 2025
[8-K] FibroBiologics, Inc. Reports Material Event

FBLG Stock Data

23.85M
33.69M
19.57%
12.23%
2.48%
Biotechnology
Pharmaceutical Preparations
Link
United States
HOUSTON